In a prespecified exploratory analysis in patients with HER2-ultralow tumors, defined as faint, incomplete membrane staining in ≤10% of tumor cells (i.e. IHC >0 and <1+), similar numerical improvements in progression-free survival and OS were observed favoring T-DXd. The gene discussed is ERBB2; the disease is neoplasm.